title: A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis.
abstract: The role of p38 mitogen-activated protein kinase (MAPK) inhibitors for treating rheumatoid arthritis (RA) is debated. Therefore, we performed a meta-analysis of all published randomized controlled trials (RCTs) to evaluate the efficacy and safety of p38 MAPK inhibitors in patients with active RA. Searches were conducted in the databases PubMed, EMBASE, and Cochrane Library. We identified three articles including four RCTs with analysis on the efficacy and safety of p38 inhibitors for the treatment of RA. Our meta-analysis showed that a better American College of Rheumatology 20% improvement (ACR20) was observed in the p38 inhibitors group compared with the placebo group, but there were no meaningful differences in ACR50, Disease Activity Score in 28 joints response, and CRP levels between two groups past week 12. The overall adverse events were similar between placebo and treatment groups. In conclusion, p38 MAPK inhibitors showed modest efficacy in patients with RA. However, this conclusion is based on the small number of available studies and inadequate sample size, and more well-designed RCTs will be necessary to determine the role of p38 MAPK inhibitors in RA.
authors.affiliation: The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People's Republic of China.
authors.forename: Lan
authors.initials: L
authors.lastname: Li
authors.forename: Guogang
authors.initials: G
authors.lastname: Li
authors.forename: Chaohui
authors.initials: C
authors.lastname: Yu
authors.forename: Youming
authors.initials: Y
authors.lastname: Li
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology*; D006801:Humans; D007249:Inflammation; D008727:Methotrexate / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016896:Treatment Outcome; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D048051:p38 Mitogen-Activated Protein Kinases; D008727:Methotrexate
references.citation: Clin Pharmacol Ther. 2012 Oct;92(4):440-2
references.pmid: 22910444
references.citation: Arthritis Rheum. 2009 Feb;60(2):335-44
references.pmid: 19180516
references.citation: Ann Rheum Dis. 2010 Feb;69(2):364-7
references.pmid: 19357113
references.citation: J Clin Pharmacol. 2010 Sep;50(9):1031-8
references.pmid: 20100913
references.citation: Gastrointest Endosc. 2008 Aug;68(2):246-54
references.pmid: 18455169
references.citation: Clin Gastroenterol Hepatol. 2006 Mar;4(3):325-34
references.pmid: 16527696
references.citation: Arthritis Rheum. 2009 May;60(5):1232-41
references.pmid: 19404957
references.citation: J Rheumatol. 2011 May;38(5):846-54
references.pmid: 21285160
references.citation: J Pharmacol Exp Ther. 2008 Dec;327(3):610-9
references.pmid: 18776065
references.citation: Arthritis Rheum. 2003 Sep;48(9):2670-81
references.pmid: 13130488
references.citation: Rheumatology (Oxford). 2012 Jul;51 Suppl 5:v3-11
references.pmid: 22718924
references.citation: Expert Opin Ther Targets. 2008 Feb;12(2):171-83
references.pmid: 18208366
references.citation: Rheumatology (Oxford). 2008 Apr;47(4):409-14
references.pmid: 18187523
references.citation: Circulation. 2011 Feb 8;123(5):515-23
references.pmid: 21262998
references.citation: Nature. 1994 Dec 22-29;372(6508):739-46
references.pmid: 7997261
references.citation: Ann Intern Med. 2001 Dec 4;135(11):982-9
references.pmid: 11730399